Author of

• 20157

  +

  P1.08 - Locally Advanced NSCLC (ID 694)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Locally Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22720

    +

    P1.08-008 - Chemoradiotherapy in the Regime of Accelerated Fractionation in the Treatment of Lung Cancer (ID 8809)

    09:30 - 09:30  |  Author(s): Y. Mardynsky
    • Abstract

    Background:
    Radiation therapy is one of the main methods of treatment of inoperable lung cancer. The standard of treatment is simultaneous chemoradiotherapy in the traditional fractionation regimen. However, the results of treatment cannot be called satisfactory - the five-year overall survival and median are about 20% and 24 months respectively. Based on radiobiological data and previous studies, it was found that accelerated fractionation regimes have advantages over the traditional regime.The purpose of this study is to improve both immediate and long-term indicators of combined treatment of patients with lung cancer by applying the accelerated fractionation regimen.
    
    Method:
    The material was based on data on the treatment of 70 patients with a verified diagnosis of inoperable lung cancer or patients with contraindications to surgical treatment. All patients underwent simultaneous or sequential radiation therapy in the regime of accelerated fractionation (daily dose of 2.4 Gy, 25 fractions, a total dose of 60 Gy) and 4-6 cycles of chemotherapy with platinum doublets (cisplatin+etoposide or carboplatin+paclitaxel) in standart doses.
    
    Result:
    Direct results of treatment were assessed using computed tomography (RECIST 1.1 criteria) at 1-3 months after the end of radiation therapy, which were: complete response in 5 (7.2%) patients, partial response in 31 (44.3%) patients, stabilization in 28 (40%), progression in 6 (8.5%). Complications: acute esophagitis stage 1 - 25.7%, stage 2 - 18.5%, stage 3 - 7.2%. Acute pneumonitis stage 1 - 10%, stage 2 - 4.5%.
    
    Conclusion:
    Thus, it can be concluded that the application of the accelerated fractionation regime is satisfactorily tolerated by patients and allows achieving high rates of immediate efficacy, as well as reducing the overall treatment time of patients.